Literature DB >> 17973330

Pallidal deep brain stimulation improves quality of life in segmental and generalized dystonia: results from a prospective, randomized sham-controlled trial.

Joerg Mueller, Inger M Skogseid, Reiner Benecke, Andreas Kupsch, Thomas Trottenberg, Werner Poewe, Gerd H Schneider, Wilhelm Eisner, Alexander Wolters, J U Müller, Günther Deuschl, Marcus O Pinsker, Geir K Roeste, Juliane Vollmer-Haase, Angela Brentrup, Martin Krause, Volker Tronnier, Alfons Schnitzler, Jüergen Voges, Guido Nikkhah, Jan Vesper, Markus Naumann, Jens Volkmann.   

Abstract

As part of the first randomized, sham-stimulation controlled trial on deep brain stimulation (DBS) in primary segmental or generalized dystonia, health-related quality of life (HRQoL) was assessed by SF-36. After the 3-month sham-controlled phase, significant HRQoL improvement occurred only in the active-stimulation group. The open-label extension phase resulted in a significant improvement in all SF-36 domains following 6 months of neurostimulation. These results demonstrate a favorable impact of DBS on HRQoL in primary dystonia. 2007 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17973330     DOI: 10.1002/mds.21783

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  32 in total

1.  Deep brain stimulation complicated by bilateral large cystic cavitation around the leads in a patient with Parkinson's disease.

Authors:  Jonathan Jagid; Karthik Madhavan; Amade Bregy; Mehul Desai; Armando Ruiz; Robert Quencer; Howard J Landy
Journal:  BMJ Case Rep       Date:  2015-10-16

2.  Targeting the brain: considerations in 332 consecutive patients treated by deep brain stimulation (DBS) for severe neurological diseases.

Authors:  Angelo Franzini; Roberto Cordella; Giuseppe Messina; Carlo Efisio Marras; Luigi Michele Romito; Alberto Albanese; Michele Rizzi; Nardo Nardocci; Giovanna Zorzi; Edvin Zekaj; Flavio Villani; Massimo Leone; Orsola Gambini; Giovanni Broggi
Journal:  Neurol Sci       Date:  2012-01-24       Impact factor: 3.307

3.  Long-term neuropsychiatric outcomes after pallidal stimulation in primary and secondary dystonia.

Authors:  Sara Meoni; Mateusz Zurowski; Andres M Lozano; Mojgan Hodaie; Yu-Yan Poon; Melanie Fallis; Valerie Voon; Elena Moro
Journal:  Neurology       Date:  2015-07-08       Impact factor: 9.910

4.  Deep-Brain Stimulation for Basal Ganglia Disorders.

Authors:  Thomas Wichmann; Mahlon R Delong
Journal:  Basal Ganglia       Date:  2011-07-01

5.  Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation.

Authors:  L Timmermann; K A M Pauls; K Wieland; R Jech; G Kurlemann; N Sharma; S S Gill; C A Haenggeli; S J Hayflick; P Hogarth; K L Leenders; P Limousin; C J Malanga; E Moro; J L Ostrem; F J Revilla; P Santens; A Schnitzler; S Tisch; F Valldeoriola; J Vesper; J Volkmann; D Woitalla; S Peker
Journal:  Brain       Date:  2010-03-05       Impact factor: 13.501

Review 6.  Alternative approaches to modeling hereditary dystonias.

Authors:  Rachel Fremont; Kamran Khodakhah
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 7.  [Deep brain stimulation for movement disorders].

Authors:  F Steigerwald; J Volkmann
Journal:  Nervenarzt       Date:  2012-08       Impact factor: 1.214

Review 8.  What's new in dystonia?

Authors:  Vicki Shanker; Susan B Bressman
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

9.  Somatotopic organization in the internal segment of the globus pallidus in Parkinson's disease.

Authors:  Kenneth B Baker; John Y K Lee; Gaurav Mavinkurve; Gary S Russo; Benjamin Walter; Mahlon R DeLong; Roy A E Bakay; Jerrold L Vitek
Journal:  Exp Neurol       Date:  2010-01-06       Impact factor: 5.330

10.  Deep brain stimulation in critical care conditions.

Authors:  Angelo Franzini; Roberto Cordella; Michele Rizzi; Carlo E Marras; Giuseppe Messina; Giovanna Zorzi; Dario Caldiroli
Journal:  J Neural Transm (Vienna)       Date:  2013-11-30       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.